Free tool
FAERS Monitor: Cablivi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761112 or its brand name (Cablivi, Caplacizumab-Yhdp). Reports on generic versions are filed under their own applications.
Reports
1,784
Serious
749
42% of reports
Hospitalization
357
Death reported
109
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use in unapproved indication619
- off label use208
- adamts13 activity decreased161
- epistaxis133
- platelet count decreased133
- fatigue111
- contusion89
- thrombotic thrombocytopenic purpura84
- headache83
- injection site pain82
- condition aggravated80
- adamts13 activity abnormal73
- injection site bruising70
- hospitalisation50
- gingival bleeding49
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 132 |
| 2020 | 194 |
| 2021 | 240 |
| 2022 | 269 |
| 2023 | 256 |
| 2024 | 236 |
| 2025 | 270 |
| 2026 | 187 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,375 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| adamts13 activity abnormalSignal | 73 | 47858.2 | 28632.4 | 681,591 |
| adamts13 activity decreasedSignal | 161 | 19386.8 | 15146.9 | 1,173,591 |
| thrombotic thrombocytopenic purpuraSignal | 84 | 287.9 | 233.0 | 23,169 |
| gingival bleedingSignal | 49 | 42.4 | 32.2 | 1,936 |
| product use in unapproved indicationSignal | 619 | 29.5 | 27.7 | 17,186 |
| epistaxisSignal | 133 | 21.0 | 17.8 | 2,518 |
| platelet count decreasedSignal | 133 | 14.7 | 12.5 | 1,695 |
| contusionSignal | 89 | 10.9 | 8.9 | 794 |
| injection site bruisingSignal | 70 | 10.4 | 8.2 | 584 |
| hospitalisationSignal | 50 | 3.8 | 2.9 | 103 |
| injection site painSignal | 82 | 3.2 | 2.6 | 120 |
| condition aggravatedSignal | 80 | 3.1 | 2.5 | 114 |
| off label useSignal | 208 | 2.8 | 2.5 | 249 |
| fatigue | 111 | 1.7 | 1.4 | 31 |
| headache | 83 | 1.6 | 1.3 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.